[go: up one dir, main page]

WO2018183435A1 - Vaccins bivalents à base de vlp contre le virus ebola et leurs procédés de fabrication et d'utilisation - Google Patents

Vaccins bivalents à base de vlp contre le virus ebola et leurs procédés de fabrication et d'utilisation Download PDF

Info

Publication number
WO2018183435A1
WO2018183435A1 PCT/US2018/024747 US2018024747W WO2018183435A1 WO 2018183435 A1 WO2018183435 A1 WO 2018183435A1 US 2018024747 W US2018024747 W US 2018024747W WO 2018183435 A1 WO2018183435 A1 WO 2018183435A1
Authority
WO
WIPO (PCT)
Prior art keywords
ebola
composition
vlp
cell line
gag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/024747
Other languages
English (en)
Inventor
Karnail SINGH
Paul Spearman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Priority to EP18778205.7A priority Critical patent/EP3600406A4/fr
Priority to CA3056927A priority patent/CA3056927A1/fr
Priority to US16/494,841 priority patent/US11129886B2/en
Publication of WO2018183435A1 publication Critical patent/WO2018183435A1/fr
Anticipated expiration legal-status Critical
Priority to US17/411,097 priority patent/US11890337B2/en
Priority to US18/392,463 priority patent/US12280100B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/12011—Betaretrovirus, e.g. mouse mammary tumour virus
    • C12N2740/12023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • Ebolaviruses have caused epidemics in humans that are characterized by high mortality rates.
  • the 2013-2016 Ebolavirus epidemic in West Africa resulted in more than 28,600 infections and 11,300 deaths (WHO June 2016).
  • the extent of the outbreak coupled with a high rate of mortality emphasized the importance of developing new therapeutics and preventive vaccines against Ebolaviruses.
  • Several candidate Ebola vaccines have shown protection in the non-human primate (NHP) model of Ebola.
  • Three of the most promising live attenuated vaccines for Ebola are those derived from Vesicular stomatitis virus (VSV), Chimp Adenovirus Type 3 (ChAd3), and Modified Vaccinia Ankara (MVA).
  • VSV Vesicular stomatitis virus
  • ChoAd3 Chimp Adenovirus Type 3
  • MVA Modified Vaccinia Ankara
  • virus-like particle (VLP)-based bivalent vaccine compositions may comprise a spherical retroviral Group- specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins.
  • Gag Group-specific Antigen
  • glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens.
  • the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
  • FIG. 1 Inducible expression of EBOV GP, SUDV GP and HIV-1 Gag in ESGPGag 293F cells. Cells were cultured as such or induced with Dox for 24 h and cell ly sates probed by western blotting for EBOV GP, SUDV GP, HIV-1 Gag and actin using specific antibodies.
  • FIG. 1 Dox induced secretion of ESGPGag VLPs containing EBOV GP, SUDV GP and HIV-1 Gag by ESGPGag 293F cells. Supernatant from cells induced with Dox was layered on 20% sucrose cushion and subjected to ultracentrifugation. VLP pellets so obtained and the cell lysates were probed by western blotting using anti-EBOV GP, anti- SUDV GP and anti-HIV-1 Gag specific antibodies.
  • FIG 3. Buoyance density analysis of ESGPGag VLPs. Fractions collected after ultracentrifugation of ESGPGag VLPs over 20-60% sucrose gradient were probed by western blotting using anti-EBOV GP, anti-SUDV GP and anti-HIV-1 Gag specific antibodies.
  • ESGPGag VLPs were found to have a buoyance density between 1.136- 1.180 with the peak at 1.153 [0010] FIG 4.
  • Negative electron microscopy of ESGPGag VLPs VLPs harvested from culture supernatants after ultracentrifugation on 20% sucrose cushion were analyzed by negative electron microscopy. The analysis showed spherical particles abundantly covered with spikes of glycoproteins on their surface.
  • FIG. Immunoreactivity of rabbit anti-ESGPGag VLP sera with recombinant Ebola glycoproteins. Elisa plates were coated with 20 ng/well of either recombinant EBOV GPdTM or SUDV GPdTM proteins, blocked and incubated with increasing dilutions of rabbit anti-ESGPGag VLP sera. Protein bound antibodies were detected by incubating the wells with horse radish peroxidase (HRP) bound anti-rabbit IgG detecting antibodies followed by the addition of HRP substrate and measuring the optical density at 450 nm.
  • HRP horse radish peroxidase
  • FIG. Rabbit anti-ESGPGag VLP sera strongly neutralize all four species of Ebolavirus pathogenic to humans. EBOV, SUDV, BDBV, TAFV and MARV GP containing HIV- ⁇ pseudo virions were incubated with different dilutions of rabbit anti-ESGPGag VLP sera for one hour and then added onto TZM-bl cells that express luciferase under the control of HIV-1 Tat. 48 hours later luciferase activity was measured and percentage neutralization calculated by comparing luciferase activity in the test wells to that in the wells that received respective pseudovirions that was not incubated with any antibody/serum.
  • the term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, or up to 10%, or up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5- fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term "about” meaning within an acceptable error range for the particular value should be assumed.
  • the term "effective amount” means the amount of one or more active components that is sufficient to show a desired effect. This includes both therapeutic and prophylactic effects. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
  • the term refers to a human patient, but the methods and compositions may be equally applicable to non-human subjects such as other mammals. In some embodiments, the terms refer to humans. In further embodiments, the terms may refer to children.
  • Ebola virus disease is caused by Ebola viruses that are filamentous, negative- strand RNA viruses belonging to the family Filoviridae.
  • Ebola viruses There are five species of the Ebola viruses; Zaire ebolavirus (EBOV), Sudan ebolavirus (SUDV), Bundibugiyo ebolavirus (BDBV), Tai-forest ebolavirus (TAFV) and Reston ebolavirus (RESTV).
  • EBOV Zaire ebolavirus
  • SUDV Sudan ebolavirus
  • BDBV Bundibugiyo ebolavirus
  • TAFV Tai-forest ebolavirus
  • RESTV Reston ebolavirus
  • Ebolavirus structure consists of an inner nucleocapsid made up of nucleoprotein (NP) and containing the viral RNA, along with RNA polymerase L, transcription factor VP30 and cofactor VP35.
  • the viral nucleocapsid is surrounded by a lipid bilayer that contains the envelope protein spikes of glycoprotein (GP). Between the viral envelope and nucleocapsid are the matrix proteins VP40 and VP24 (1). Because of its integral role in the pathogenesis of EVD, GP has been the relevant target of all the candidate Ebola vaccines developed so far.
  • Ebola vaccines have been developed and evaluated in non-human primate (NHP) model of EVD as well as in clinical trials (2-11). A few of them were fast tracked to the clinical trials during the 2013-2016 Ebola epidemic.
  • Ebola vaccines such as the vesicular stomatitis virus (VSV), adenovirus 5 (Ad5) or chimpanzee adenovirus 3 (ChAd3)-vectored vaccines appear quite promising in generating protective immune responses.
  • VSV vesicular stomatitis virus
  • Ad5 adenovirus 5
  • ChoAd3-vectored vaccines appear quite promising in generating protective immune responses.
  • each candidate has substantial limitations.
  • the VSV vaccine elicits a high rate of adverse events so that acceptability for licensure remains in doubt (2, 3)
  • Recombinant human adenoviral vectored vaccines are limited by pre-existing immunity to the vector in the human populations at risk for Ebola (4).
  • Chimpanzee adenovirus based Ebola vaccine like ChAd3-EBO and ChAd3-EBO-Z have been developed to bypass the pre-existing immunity to the vector in the humans.
  • Ebola virus disease Ebola virus disease
  • Boosting of animals after priming with this vaccine with Modified Vaccinia Ankara (MVA)-Filo vaccine that has glycoproteins (GP) from Zaire (EBOV), Sudan (SUDV) and Marburg (MARV) viruses and nucleoprotein from Tai-Forest (TAFV) virus has been shown to extend the duration of protective immune responses against lethal EBOV challenge (11).
  • VLP virus-like particle
  • GP Ebola glycoproteins
  • SUDV Sudan
  • I:C adjuvants Poly
  • CpG adjuvants Poly
  • Immunization of rabbits produced high titered binding anti-EBOV GP and anti-SUDV GP antibodies that neutralized all four pathogenic species of Ebolavirus.
  • This VLP-based vaccine product is an ideal reagent to employ either as a stand-alone Ebola vaccine or in combination (prime -boost) with other experimental Ebola vaccines and has high commercial potential.
  • the disclosed VLP platform may be used for large-scale production of a nanoparticle bivalent Ebola vaccine.
  • the production system is based on a stable and inducible ESGPGag 293F cell line that, upon induction with doxycycline (Dox), secretes VLPs with HIV-1 Gag core abundantly studded with Ebola glycoproteins (GPs) from Zaire (EBOV) and Sudan (SUDV) Ebolaviruses.
  • the Gag core provides a very stable framework of ⁇ 1 lOnm on which Ebola GPs are incorporated in their native conformation.
  • Initial immunogenicity results in rabbits are highly promising, with high binding titers and substantial neutralization elicited against all the four pathogenic Ebolavirus species.
  • the ESGPGag 293F stable cell production system can be easily scaled up to produce large quantities of clinical grade Ebola VLPs.
  • the spherical Gag core exhibits enhanced stability as compared with other framework constructs such as Ebola VP40 protein.
  • the VLP-based vaccines are non-infectious, have antigen in stable and native conformation, and do not suffer from the limitation of pre-existing immunity.
  • This bivalent Ebola vaccine may provide protection as a stand-alone vaccine, or may be even more advantageous when provided as a booster vaccine following priming with other experimental Ebola vaccines.
  • virus-like particle (VLP)-based bivalent vaccine compositions may comprise a spherical retroviral Group- specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins.
  • Gag Group-specific Antigen
  • glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens.
  • the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
  • EBOV Zaire
  • SUDV Sudan
  • An exemplary Gag protein includes, but is not limited to, that of SEQ ID NO: 1.
  • Exemplary glycoproteins include, but are not limited to, those set forth in SEQ ID NOS 2, 3, and 4.
  • sequences having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity may include the sequences disclosed herein or as otherwise known in the art.
  • the length of comparison sequences may be at least 5 contiguous nucleotides or amino acids, or at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides or amino acids, or the full-length nucleotide or amino acid sequence.
  • Sequence identity may be measured using sequence analysis software on the default setting (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). Such software may match similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications.
  • the Gag protein may be derived from a retrovirus.
  • suitable retroviruses from which the gag protein may be derived include human
  • HIV immunodeficiency virus
  • MMV murine leukemia virus
  • RSV Rous sarcoma virus
  • EIAV Equine infectious anemia virus
  • the glycoproteins are capable of aggregating at a relatively high density at the surface of the spherical gag core.
  • the EBOV GP Concentration may be about 20 to about 60 ug/ml, or about 20 to about 50 ug/ml, for example, in one aspect, 22-50 ug/ml.
  • the SUDV GP Concentration may be about 1 to about 15 ug/ml, or about 2 to about 12 ug/ml, or, for example, in one aspect, 3 to 11 ug/ml.
  • the HIV-1 Gag Concentration may be about 2 to about 20 ug/ml, or about 3 to about 18 ug/ml, or for example, in one aspect, 4 to 15 ug/ml.
  • the concentrations of EBOV GP and SUDV GP may be measured by semi-quantitative western blotting using known quantities of purified recombinant EBOV GP and SUDV GP respectively.
  • Concentrations of HIV-1 Gag VLPs may be measured by an HIV-1 Gag specific ELISA using known quantities of purified HIV- 1 Gag.
  • the spherical Gag protein core may have a diameter of from about 100 to about 300 nanometers.
  • the VLP composition while containing only the EBOV and SUDV glycoproteins, may be sufficient to immunize an individual against a viral infection from one or more of Zaire (EBOV), Sudan (SUDV), Bundibugyo (BDBV) and Tai Forest (TAFV), or in some aspects, two or more of Zaire (EBOV), Sudan (SUDV), Bundibugyo (BDBV) and Tai Forest (TAFV), or three or more of Zaire (EBOV), Sudan (SUDV), Bundibugyo (BDBV) and Tai Forest (TAFV), or all four of Zaire (EBOV), Sudan (SUDV), Bundibugyo (BDBV) and Tai Forest (TAFV).
  • EBOV Zaire
  • SUDV Sudan
  • Bundibugyo BDBV
  • Tai Forest Tai Forest
  • compositions may further comprise one or more
  • compositions may further include a stabilizing agent, such as for example saccharides, trehalose, mannitol, saccharose and the like, to increase and/or maintain product shelf-life.
  • compositions herein may incorporate known injectable, physiologically acceptable sterile solutions.
  • aqueous isotonic solutions such as e.g. saline or corresponding plasma protein solutions are readily available.
  • the immunogenic and vaccine compositions of the present invention can include diluents, isotonic agents, stabilizers, or adjuvants.
  • Diluents can include water, saline, dextrose, ethanol, glycerol, and the like.
  • Isotonic agents can include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others.
  • Stabilizers include albumin and alkali salts of ethylendiamintetracetic acid, among others. Suitable adjuvants will be appreciated by one of ordinary skill in the art.
  • a container comprising at least one dose of the immunogenic compositions disclosed herein.
  • the container may comprise 1 to 250 doses of the immunogenic composition, or in other aspects, 1, 10, 25, 50, 100, 150, 200, or 250 doses of the immunogenic composition.
  • each of the containers may comprise more than one dose of the immunogenic composition and may further comprises an anti- microbiological active agent.
  • Those agents may include, for example, antibiotics such as Gentamicin and Merthiolate and the like.
  • kits may comprise any of the containers described above and an instruction manual, including the information for the delivery of the immunogenic composition disclosed above.
  • kits and/or compositions may further include an immune stimulant such as keyhole limpet hemocyanin (KLH), or incomplete Freund's adjuvant (KLH/ICFA). Any other immune stimulant known to a person skilled in the art may also be used.
  • KLH keyhole limpet hemocyanin
  • KLH/ICFA incomplete Freund's adjuvant
  • a method for eliciting an immune response an individual in need thereof against an Ebola virus species selected from Zaire (EBOV), Sudan (SUDV), Bundibugyo (BDBV), Tai Forest (TAFV), and combinations thereof is disclosed.
  • the method may comprise the step of administering a composition as disclosed herein.
  • the method may include the step of administering a vaccine composition as disclosed above to an individual in need thereof.
  • the disclosed compositions may be administered to an individual according to any method known in the art, and that optimal administration (including route and amounts) will not require undue experimentation.
  • the vaccine compositions may be administered prophylactically to an individual suspected of having a future exposure to the antigen incorporated into the vaccine composition.
  • Dosage regimen may be a single dose schedule or a multiple dose schedule (e.g., including booster doses) with a unit dosage form of the composition administered at different times.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of the antigenic compositions disclosed herein in an amount sufficient to produce the desired effect, which compositions are provided in association with a pharmaceutically acceptable excipient (e.g., pharmaceutically acceptable diluent, carrier or vehicle).
  • the vaccine may be administered in conjunction with other immunoregulatory agents.
  • the dosage regimen may take a variety of different forms.
  • the individual may be administered a first dose of the disclosed composition followed by a second dose of the composition.
  • the second dose may be administered at a second point in time selected from a day after the first dose, a week after the first dose, two weeks after the first dose, three weeks after the first dose, and four weeks after the first dose.
  • a method of making the bivalent VLP compositions may comprise the steps of purifying from a cell line culture a VLP composition comprising a spherical retroviral Group-specific Antigen ("Gag”) protein core and at least two Ebola glycoproteins, wherein said at least two Ebola glycoproteins are incorporated into the surface of the spherical Gag protein core.
  • Gag Group-specific Antigen
  • the cell line may be stably transfected with a first plasmid containing a gag sequence under the control of an inducible promoter, a second plasmid containing an Ebola glycoprotein sequence under the control of an inducible promoter, and a third plasmid containing an Ebola glycoprotein sequence under the control of an inducible promoter, the second and third plasmid may contain different Ebola
  • the stably transfected cell line may produce the spherical Gag protein core and the at least two Ebola glycoproteins.
  • the at least two Ebola glycoproteins self-assemble at the surface of said spherical Gag protein core.
  • the first plasmid, second plasmid, and third plasmid may be antibiotic resistant. This antibiotic resistance allows the cells stably transfected with the three plasmids to grow in a selection media containing the three antibiotics.
  • the stably transfected cell line may produce the Gag protein core upon induction with doxycycline.
  • the VLP produced by the cell lines may be purified by ultracentrifugation.
  • the purification may be via a sucrose cushion, such as, for example a 20% sucrose cushion, or by cross-flow filtration followed by ultracentrifugation.
  • the cell line may be a human cell line modified to stably express Gag, EBOV GP, and SUDV GP under inducible promoters.
  • the cell line may be a 293F cell line, in a further aspect, the cell line may be a 293F 6/TR cell line
  • a cell line comprising a first plasmid containing a sequence encoding for a gag protein under the control of an inducible promoter, a second plasmid containing a sequence encoding for a first Ebola glycoprotein under the control of an inducible promoter, and a third plasmid containing a sequence encoding for a second Ebola glycoprotein under the control of an inducible promoter.
  • the Ebola glycoprotein may be Zaire (EBOV).
  • the cell line may further contain a third plasmid containing a sequence encoding for a second Ebola glycoprotein under the control of an inducible promoter, wherein the second Ebola glycoprotein is SUDV.
  • the cell line may be a human cell line modified to stably express Gag, EBOV GP, and SUDV GP under inducible promoters.
  • the cell line may be a 293F cell line, in a further aspect, the cell line may be a 293F 6/TR cell line the cell line may be stably transfected with the plasmids.
  • the cell line may be an inducible cell line. Any of the aforementioned sequences may be codon-optimized. Codon optimization is readily understood by one of ordinary skill in the art, described, for example, at
  • Plasmids The HIV-1 Gag gene was introduced between Hindlll and BamHI sites of plasmid pcDNA4/TO (Invitrogen, Carlsbad, CA) to generate plasmid pcDNA4/TO HIV-1 Gag.
  • pcDNA5/TO-puro and pcDNA5/TO-neo plasmids were created by replacing hygromycin resistance gene sequence of original pcDNA5/TO vector (Invitrogen, Carlsbad, CA) with a puromycin and neomycin resistance genes, respectively. Briefly, the puromycin or neomycin resistance gene was amplified by polymerase chain reaction (PCR).
  • Codon-optimized EBOV GP Mayinga gene was synthesized by GenScript (Piscataway, NJ) and placed under a tetracycline- controlled cytomegalovirus (CMV) promoter into plasmid pcDNA5/TO-puro using BamHI and EcoRI sites to generate the plasmid pcDNA5/TO-puro EBOV GP.
  • GenScript Procataway, NJ
  • CMV cytomegalovirus
  • Codon-optimized SUDV GP Gulu gene was purchased from Sino-Biological (Beijing, China) and placed under a tetracycline-controlled cytomegalovirus (CMV) promoter into plasmid pcDNA5/TO-neo using Hindlll and Xbal sites to generate the plasmid pcDNA5/TO-neo SUDV GP.
  • CMV cytomegalovirus
  • the cells were washed and transferred into the selection media (293 Expression Media supplemented with 5 g/ml blasticidin, 10 ⁇ g/ml Zeocin (Invivogen), 1.0 ⁇ g/ml puromycin (Invivogen) and 500 ⁇ g/ml G418 (Invivogen)).
  • Cells were selected and expanded over the coming weeks till their number reached ⁇ 10 xlO 6 . A part of the cells was harvested and aliquots cryopreserved in liquid nitrogen.
  • Remaining cells were continued in the cultured and then either left untreated or induced with Dox (2 ⁇ g/ml) (Sigma-Aldrich) for 24 hours, cells harvested and cell lysates tested for EBOV GP, SUDV GP and HIV-1 Gag expression by western blotting using specific antibodies.
  • Cell cultures with high EBOV GP, SUDV GP and HIV-1 Gag expression were selected and labeled ESGPGag 293F cells, expanded and selected for further work. Multiple aliquots of these cells were cryopreserved in liquid nitrogen.
  • ESGPGag 293F cells were cultured in 293 Expression Media in Erlenmeyer flasks to a density of 1.5x106 cells per ml and cultures induced with Dox (2 ⁇ g/ml). 40 hours later, cells and supernatants were separated by high-speed centrifugation. Harvested cells were lysed and cell lysates frozen in -80°C freezer. The supernatant was cleared by centrifugation and by passing through 0.45 micron filtration unit.
  • ESGPGag VLPs Production and characterization of ESGPGag VLPs: Once confirmed for ESGPGag VLP secretion, ESGPGag 293F cell cultures were scaled up, VLP pellets collected as described above and layered on a 20-60% sucrose gradient in ultracentrifuge tubes. Tubes were centrifuged at 35,000 rpm at 4°C for 16 hours in an ultracentrifuge. After discarding the top 1.0 ml, twelve 900 ⁇ fractions were collected in clean tubes. Buoyance density of each fraction was determined by using a refractometer. Fractions were probed by western blotting using anti-EBOV GP, anti-SUDV GP and anti-HIV-1 Gag specific antibodies.
  • VLPs collected after centrifugation on 20% sucrose cushion were analyzed by negative-stain electron microscopy for their shape and size.
  • VLPs from eleven runs were pooled and quantified for EBOV GP and SUDV GP contents by quantitative western blotting using known amounts of recombinant EBOV GP protein and SUDV GP protein as the standards and specific antibodies.
  • Binding antibodies ELISA binding antibody titers against EBOV GP and SUDV GP were quantified by ELISA using purified recombinant GPs as the coating antigens. Briefly, ELISA plates were coated with 100 ⁇ /well of 200 ng/ml of recombinant EBOV GP and SUDV GP. Wells were blocked and incubated for 2 hours at 37°C with increasing dilutions of rabbit anti-ESGPGag VLP sera.
  • Protein bound antibodies were detected by incubating the wells with optimally diluted horse radish peroxidase (HRP) bound anti-rabbit IgG detecting antibodies followed by the addition of TMB substrate, stopping the reaction with H2SO4 and measuring the optical density at 450 nm. Specificity of the antibodies was determined by analyzing their reactivity with recombinant EBOV GP or SUDV GP in a western blot system.
  • HRP horse radish peroxidase
  • Neutralizing antibody titers were evaluated by using rHIV- ⁇ pseudovirions expressing EBOV or SUDV GP in a TZM-bl pseudovirus reporter cell method. rHIV- ⁇ pseudovirions expressing BDBV, TAFV or MARV GP were included to study the ability of anti-ESGPGag VLP sera to cross-neutralize other pathogenic Ebolaviruses as well as MARV.
  • Pseudovirions were incubated with different dilutions of rabbit anti-ESGPGag VLP sera for one hour at 37°C and then added onto confluent TZM-bl cells that express luciferase under the control of an HIV-1 Tat protein. 48 hours later luciferase activity was measured after the addition of the luciferase substrate and percentage neutralization calculated by comparing luciferase number in test wells with those in the wells that received the respective pseudovirion that was not incubated with any antibody/serum. Serum antibody titers giving 50% neutralization were calculated.
  • VLPs were isolated from the cell supernatant collected after 40 hours of Dox induction and were analyzed, along with the corresponding cell lysates, by western blotting for the presence EBOV GP, SUDV GP and HIV-1 Gag proteins using specific antibodies.
  • ESGPGag VLPs Immunogenicity of ESGPGag VLPs was tested by their ability to induce high-titered binding anti-EBOV GP and SUDV GP antibody responses in rabbits. Rabbit serum samples collected one week after the last booster dose were heat inactivated and binding titers determined by analyzing the binding of antibodies present in increasing dilutions of the anti-sera to EBOV GP and SUDV GP coated ELISA plates. As shown in FIG 5, ESGPGag VLPs were highly immunogenic in rabbits and anti- sera collected had anti-EBOV GP and SUDV GP end point antibody titers of 1 : 10 6 .
  • FIG 6 summarizes the results of neutralization experiments.
  • Anti-ESGPGag VLP serum strongly neutralized EBOV, BDBV and TAFV with 50% neutralization titers of higher than 1 : 1920.
  • 50% neutralization titer for SUDV was slightly lower (1 : 480).
  • No neutralization was observed with MARV.
  • Applicant has previously observed that rabbit anti-sera against monovalent EGPGag VLPs, that have EBOV GP on HIV-1 Gag core, strongly neutralized EBOV, BDBV and TAFV while much higher serum concentration is needed to neutralize SUDV (unpublished data).
  • Ebola VLP-based vaccine on Ebola VP40 core has been used in the past to immunize non-human primates that were subsequently challenged with lethal doses of Ebola virus. This vaccine induced humoral and cellular immune responses in animals that protected these animals against the Ebola challenge (12, 13). Because of the filamentous nature of the VP40 core, these VLPs were found to be unstable. Moreover, they were produced after the transient transfection of the cells and therefore are not readily amenable to large-scale production. VLPs may be produced, in an inducible fashion, from the stably transfected ESGPGag 293F cells. This production system can be easily adapted to large scale Ebola VLPs production, if needed. Being smaller in size and spherical in shape they are likely to be a stable and homogenous product.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions de vaccin bivalent à base de pseudo-particules virales (VLP). Les compositions peuvent comprendre un noyau protéique de l'antigène « Gag » sphérique et au moins deux glycoprotéines du virus Ebola. Lesdites au moins deux glycoprotéines du virus Ebola peuvent être situées au niveau de la surface extérieure du noyau protéique Gag sphérique, de sorte que le vaccin à base de VLP présente au moins deux antigènes de glycoprotéine du virus Ebola. Dans un aspect, lesdites au moins deux glycoprotéines du virus Ebola sont une glycoprotéine du virus Ebola Zaïre (EBOV) et une glycoprotéine du virus Ebola Soudan (SUDV).
PCT/US2018/024747 2017-03-28 2018-03-28 Vaccins bivalents à base de vlp contre le virus ebola et leurs procédés de fabrication et d'utilisation Ceased WO2018183435A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP18778205.7A EP3600406A4 (fr) 2017-03-28 2018-03-28 Vaccins bivalents à base de vlp contre le virus ebola et leurs procédés de fabrication et d'utilisation
CA3056927A CA3056927A1 (fr) 2017-03-28 2018-03-28 Vaccins bivalents a base de vlp contre le virus ebola et leurs procedes de fabrication et d'utilisation
US16/494,841 US11129886B2 (en) 2017-03-28 2018-03-28 VLP-based bivalent Ebola vaccines and methods of making and using same
US17/411,097 US11890337B2 (en) 2017-03-28 2021-08-25 VLP-based bivalent ebola vaccines and methods of making and using same
US18/392,463 US12280100B2 (en) 2017-03-28 2023-12-21 VLP-based bivalent Ebola vaccines and methods of making and using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477480P 2017-03-28 2017-03-28
US62/477,480 2017-03-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/494,841 A-371-Of-International US11129886B2 (en) 2017-03-28 2018-03-28 VLP-based bivalent Ebola vaccines and methods of making and using same
US17/411,097 Division US11890337B2 (en) 2017-03-28 2021-08-25 VLP-based bivalent ebola vaccines and methods of making and using same

Publications (1)

Publication Number Publication Date
WO2018183435A1 true WO2018183435A1 (fr) 2018-10-04

Family

ID=63677003

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2018/024758 Ceased WO2018183443A1 (fr) 2017-03-28 2018-03-28 Vaccins monovalents à base de vlp contre ebola et leurs procédés de préparation et d'utilisation
PCT/US2018/024747 Ceased WO2018183435A1 (fr) 2017-03-28 2018-03-28 Vaccins bivalents à base de vlp contre le virus ebola et leurs procédés de fabrication et d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2018/024758 Ceased WO2018183443A1 (fr) 2017-03-28 2018-03-28 Vaccins monovalents à base de vlp contre ebola et leurs procédés de préparation et d'utilisation

Country Status (4)

Country Link
US (4) US11129886B2 (fr)
EP (2) EP3600367A4 (fr)
CA (2) CA3056927A1 (fr)
WO (2) WO2018183443A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183443A1 (fr) 2017-03-28 2018-10-04 Children's Hospital Medical Center Vaccins monovalents à base de vlp contre ebola et leurs procédés de préparation et d'utilisation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216702A1 (en) * 2002-05-17 2006-09-28 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US20090210952A1 (en) * 2005-12-16 2009-08-20 Xiaoyun Wu Compositions and Methods Related to Controlled Gene Expression Using Viral Vectors
WO2015066715A1 (fr) * 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Pseudo-particules virales et procédés qui leur sont associés
US20150335726A1 (en) * 2012-04-12 2015-11-26 David B. Weiner Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same
US20160040134A1 (en) * 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
WO2016168187A1 (fr) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Particules de type virus
WO2017015457A1 (fr) * 2015-07-21 2017-01-26 Modernatx, Inc. Vaccin contre le virus ebola

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2035565A4 (fr) 2006-06-30 2010-07-21 Novavax Inc Procédés d'amélioration de l'incorporation de protéines dans des particules de type virus (vlp)
WO2012122858A1 (fr) * 2011-03-17 2012-09-20 中国科学院上海巴斯德研究所 Procédé de production d'une particule apparentée à un virus par utilisation de cellule de drosophila et ses applications
WO2018183443A1 (fr) 2017-03-28 2018-10-04 Children's Hospital Medical Center Vaccins monovalents à base de vlp contre ebola et leurs procédés de préparation et d'utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216702A1 (en) * 2002-05-17 2006-09-28 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US20090210952A1 (en) * 2005-12-16 2009-08-20 Xiaoyun Wu Compositions and Methods Related to Controlled Gene Expression Using Viral Vectors
US20150335726A1 (en) * 2012-04-12 2015-11-26 David B. Weiner Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same
WO2015066715A1 (fr) * 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Pseudo-particules virales et procédés qui leur sont associés
US20160040134A1 (en) * 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
WO2016168187A1 (fr) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Particules de type virus
WO2017015457A1 (fr) * 2015-07-21 2017-01-26 Modernatx, Inc. Vaccin contre le virus ebola

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3600406A4 *

Also Published As

Publication number Publication date
EP3600367A1 (fr) 2020-02-05
US20200085937A1 (en) 2020-03-19
EP3600406A4 (fr) 2021-01-13
US20210386849A1 (en) 2021-12-16
CA3056927A1 (fr) 2018-10-04
US20240131141A1 (en) 2024-04-25
US12427190B2 (en) 2025-09-30
CA3057138A1 (fr) 2018-10-04
US11129886B2 (en) 2021-09-28
EP3600367A4 (fr) 2021-01-13
EP3600406A1 (fr) 2020-02-05
WO2018183443A1 (fr) 2018-10-04
US12280100B2 (en) 2025-04-22
US20200085936A1 (en) 2020-03-19
US11890337B2 (en) 2024-02-06

Similar Documents

Publication Publication Date Title
US20210317169A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
JP4430942B2 (ja) インフルエンザウイルスベクターのパッケージングのためのシグナル
JP2023109845A (ja) 組換えの生物学的に封じ込められたフィロウイルスワクチン
IL298333A (en) A viral assembly vector for a vaccine against the corona virus cell
US11253587B2 (en) Vaccine compositions for the treatment of coronavirus
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
JP2024542478A (ja) リボ核酸呼吸器合胞体ウイルス（ｒｓｖ）ワクチンの組成物および方法
US20180326040A1 (en) Influenza virus vaccine and vaccine platform
JP2024530047A (ja) ワクチン抗原
US12280100B2 (en) VLP-based bivalent Ebola vaccines and methods of making and using same
US11274282B2 (en) Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
Chen et al. Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins
JP2023529124A (ja) コロナウイルスワクチンコンストラクトおよびこれを作製し使用する方法
US10842862B2 (en) Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)
US20230390383A1 (en) Replication incompetent influenza vaccine platform for foreign protein delivery
RU2701953C1 (ru) Способ получения поливалентной вакцины от гриппа
US20130243808A1 (en) Compositions and methods for vaccinating humans and animals against enveloped viruses
US20220380410A1 (en) Live Attenuated Universal Influenza Virus Vaccines, Methods and Uses Thereof
RU2681439C1 (ru) Вирусоподобная частица вируса гриппа и способ ее получения
RU2706191C1 (ru) Поливалентная вакцина против гриппа
RU2706544C1 (ru) Концентрат вакцины от гриппа и способ его получения
JP4456169B2 (ja) インフルエンザウイルスベクターのパッケージングのためのシグナル
RU2701959C1 (ru) Способ контроля получения продукта вакцина от гриппа
RU2680537C1 (ru) Лентивирусная плазмида (варианты), способ ее получения (варианты), набор праймеров для получения лентивирусного плазмидного вектора (варианты)
RU2681482C1 (ru) MDCK клетка-продуцент белков вируса гриппа (варианты)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18778205

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3056927

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018778205

Country of ref document: EP

Effective date: 20191028